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Abstract
Objectives To identify the policies of major pharmaceutical companies
on transparency of trials, to extract structured data detailing each
companies’ commitments, and to assess concordance with ethical and
professional guidance.
Design Structured audit.
Setting Pharmaceutical companies, worldwide.
Participants 42 pharmaceutical companies.
Main outcome measures Companies’ commitments on sharing
summary results, clinical study reports (CSRs), individual patient data
(IPD), and trial registration, for prospective and retrospective trials.
Results Policies were highly variable. Of 23 companies eligible from
the top 25 companies by revenue, 21 (91%) committed to register all
trials and 22 (96%) committed to share summary results; however,
policies commonly lacked timelines for disclosure, and trials on
unlicensed medicines and off-label uses were only included in six (26%).
17 companies (74%) committed to share the summary results of past
trials. The median start date for this commitment was 2005. 22
companies (96%) had a policy on sharing CSRs, mostly on request: two
committed to share only synopses and only two policies included
unlicensed treatments. 22 companies (96%) had a policy to share IPD;
14 included phase IV trials (one included trials on unlicensed medicines
and off-label uses). Policies in the exploratory group of smaller
companies made fewer transparency commitments. Two companies fell
short of industry body commitments on registration, three on summary
results. Examples of contradictory and ambiguous language were
documented and summarised by theme. 23/42 companies (55%)
responded to feedback; 7/1806 scored policy elements were revised in
light of feedback from companies (0.4%). Several companies committed
to changing policy; some made changes immediately.
Conclusions The commitments made by companies to transparency
of trials were highly variable. Other than journal submission for all trials
within 12 months, all elements of best practice were met by at least one
company, showing that these commitments are realistic targets.
Introduction
Themethods and results of completed clinical trials are routinely
left unpublished.1 This is a longstanding structural problem that
impacts negatively on patient care.2 3Anecdotally there is a wide
range of variation in policies and actions on trial transparency
between different companies. For example, GlaxoSmithKline
has publicly committed to share clinical study reports (CSRs)
for all clinical trials back to 2000,4 and it has set up a unit within
the company to deliver this.5 In contrast, AbbVie and Intermune
sued the European Medicines Agency in a bid to prevent the
regulator from disclosing the equivalent documents.6
Audit is a simple tool that is widely used throughout medicine
to help improve standards by establishing a reference standard,
against which performance can be measured.7 Through audit,
those performing badly can be targeted for action to improve
standards, and those performing to the highest standards can be
identified, so that others can learn from their best practice. Audit
data can be used by stakeholders such as regulators, patient
groups, professional bodies, ethical investors, and healthcare
workers to advocate for improvements in poorly performing
companies and to help improve standards—for example, by
informing individual consumer decisions and policy activity,8
or by informing decisions made by ethical investors, as
exemplified by the Access to Medicines Index.9 There have
been calls for audits of access to trial results for performance
monitoring and comparison,8 with several recent examples
including trials from individual research centres,10 11 12 all drugs
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approved in one year,13 and all trials approved by individual
ethics committees.14 No attempts have, however, been made to
systematically compare funder or sponsor policies on
transparency.
We identified pharmaceutical companies’ policies on access to
information about clinical trials and extracted structured data
characterising their commitments to register clinical trials, share
summary results, share CSRs, and give access to trial data for
current and past trials (box 1); and we assessed concordance
with ethical and professional guidance.
Methods
Search strategy
We set out to include 50 companies: the top 25 pharmaceutical
companies by global sales29 and an arbitrary selection of smaller
companies for exploratory analysis of smaller firms’ policies.
Baxter was excluded as it no longer makes pharmaceutical
products and Teva was excluded as it is principally a generics
company; during the audit period six smaller companies ceased
to exist, largely through merger, leaving 42 companies. We
searchedGoogle for company policies and statements on clinical
trial transparency using the key terms “company name” “clinical
trial transparency” and “company name” “clinical trials” and
by navigating through company websites for formal standalone
transparency policies. We also searched for policies on clinical
trial transparency from the European Federation of
Pharmaceutical Industries and Associations (EFPIA) and
Pharmaceutical Research and Manufacturers of America
(PhRMA). We saved archive copies of all company website
pages containing transparency commitments, downloaded
archive copies of all standalone documents such as PDFs, and
downloaded policy documents from EFPIA and PhRMA, as
they stood at 17 April 2016.
Defining the reference standard for
transparency commitments
In line with best practice for audits, we established the reference
standard for a transparency policy and developed a data structure
to reflect this standard. Our reference standard for transparency
was that all trials should be registered as per International
Committee of Medical Journal Editors (ICJME)
requirements,30 31 World Health Organisation guidance,32 33 and
legislative requirements34; with methods and results reported in
summary form within 12 months of trial completion through
online results reporting or other publication, as required under
WHO guidance,1 EU legislation,35 36 and Food and Drug
Administration Amendments Act (FDAAA) of 2007; that CSRs
should be made publicly available if they have been created, in
accordance with current EU legislation36 and various calls from
civic society and academia,23 37 and that IPD should be available
on request in some form to researchers.38 39 We then
operationalised these broad commitments into structured
questions across the four domains of registration, methods and
results sharing, CSRs, and IPD, assessing the policy
commitments on each domain in detail (see web appendix 1).
Prospective commitments and retrospective commitments were
coded separately. Because some companies’ retrospective
commitments only applied to recent trials, whereas others went
back several decades, we extracted the start dates for
retrospective commitments into our coding sheet. We also
assessed whether certain categories of trial, such as phase IV
trials conducted after approval of a new product, or trials of
unlicensed medicines and off-label uses, were included under
each policy.
Data extraction
Five experienced researchers (BG, CH, KRM, IO, and SL) with
a background in clinical trials, transparency, or research integrity
(or a combination of specialties) independently extracted the
data from retrieved documentation and websites into a data
extraction sheet reflecting the questions in web appendix 1. At
least three researchers independently extracted data, and then
met to agree the final coding by consensus. In some
circumstances it was not possible to code answers as “yes” or
“no”: these were coded as “unclear.”We attempted to minimise
use of this code and achieve consensus where possible.
Additionally, we collected examples of ambiguous,
contradictory, or problematic commitments during coding, and
grouped these by theme.
Engagement with companies
In 2015 before commencing this study we wrote to each
companies’ representatives inviting them to meet us for an hour.
This was to explain our project, allow for feedback, and ensure
that it was understood we would be collecting data on policies
and publishing our findings. In June 2016we sent the companies
the full set of data extracted for their company’s policy and
invited responses setting out any disagreements on any element,
by making reference to the text of their publicly accessible
policy as it stood at 17 April 2016. The data sent did not indicate
how the company compared with other companies. We sent
emails to the chief executive officer, medical director, and email
accounts of other individuals in relevant roles who had
previously responded to us on related queries about
transparency. All responses were read, themes and disagreements
extracted and reviewed by at least two members of the team
(BG and SL), and changes made where appropriate.
Data synthesis and analysis
We generated descriptive statistics summarising the proportion
of companies making key commitments and the extent to which
commitments applied retrospectively. For companies that were
members of an industry body, we assessed whether their policy
was consistent with the minimum commitments made by four
pharmaceutical industry bodies: EFPIA, PhRMA, International
Federation of Pharmaceutical Manufacturers and Associations
(IFPMA), and Japan PharmaceuticalManufacturers Association
(JPMA). All raw underlying data are shared online,40 permitting
others to critically review assessments or create composite
measures of overall transparency commitments to compare
companies.
Patient involvement
The development of the overall research question and outcome
measures was informed by the AllTrials campaign’s extensive
engagement with signatories and supporters, including patient
groups. Patients were not formally involved in developing the
study design.
Results
Overall, 42 companies were assessed: 22 were based in the
European Union, 13 in the USA, six in Japan, and one in
Canada. Forty companies (95%) had a publicly accessible policy,
and in total we reviewed 527 pages of policy documentation.
Table 1⇓ shows the proportion of companies that met each of
the transparency criteria. In total, 21 (91%) of the 23 top
companies by revenue had a commitment to register all trials,
15 (65%) described their registration policy covering past trials,
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Box 1: Types of information about a clinical trial
Registration is the most basic level of transparency: an entry on a publicly accessible registry to note that the trial exists, with some core
information on features such as the intervention and the patient population.15 Registration does not guarantee disclosure of results, but it can
be used by researchers to identify completed trials as a step towards establishing whether they have subsequently disclosed their results.
Methods and summary results of clinical trials can be reported in an academic paper, or as structured tables of information on registers such
as clinicaltrials.gov.16 Both methods have strengths and weaknesses.17 18 19 20 21 However, academic publication remains the most common route
for the communication of trial results.
Clinical study reports (CSRs) are large documents, sometimes thousands of pages long, which are generated for regulatory purposes and
follow a standard format set out under international guidance.22 They are routinely created for industry trials, and less well known in the academic
community, but contain a wealth of detail on methods and results that is often missing from other sources23: one recent study estimates that
CSRs contain twice as much information on benefits and harms as academic papers on trials.24 From 2010 the European Medicines Agency
began releasing CSRs on request, after a European ombudsman ruling of maladministration against the agency for withholding such information.25
Individual patient data (IPD) is the raw data collected during a clinical trial, with detailed information on each individual participant. As such it
presents important opportunities for research—for example, by allowing third parties to verify trialists’ initial analyses; permitting meta-analysis
of pooled IPD for more accurate point estimates of benefits; giving greater power for subgroup analyses; and allowing new hypotheses to be
explored in existing data, including on abandoned products and treatments.26 27 28 However, it also presents a risk of re-identification of
pseudonymised participants. Because of this, IPD is not generally posted in public but shared through various controlled access mechanisms,
as with other forms of rich electronic health record data used by epidemiologists.
and two (9%) conducted an audit of compliance. Twenty two
(96%) companies made a commitment to make all summary
results available, 17 (74%) committed to share the summary
results of past trials; however, policies commonly did not include
timelines for disclosure, and only six (26%) included trials on
unlicensedmedicines and off-label uses. Twenty two companies
(96%) had a policy on clinical study reports (CSRs), of whom
21 offered some form of sharing (17 on request and two sharing
synopses); two included trials on unlicensed medicines and
off-label uses. Twenty two companies (96%) had a policy to
share individual patient data (IPD). One included unlicensed
medicines and off-label uses and 14 included phase IV trials.
Table 1⇓ shows that the exploratory group of smaller companies
made fewer transparency commitments.
Table 2⇓ lists all the companies and policy documents coded,
and summarises whether each committed to the standards
described. The full extracted data on every company’s detailed
commitments are available online.40 The median start date for
retrospective policies on the reporting of both registration and
summary results was 2005. The median start date for sharing
of both CSRs and IPD was 2012. Table 3⇓ shows the range of
the start dates for policy commitments.
Problematic, inaccurate, and contradictory
language
Table 4⇓ gives examples of problematic, inaccurate, and
contradictory language in policy documents, grouped by theme
(see web appendix 2 for a longer list). Several policies used the
word “all” problematically: it was stated or implied in one place
that a commitment applied to “all” trials but then a caveat was
applied elsewhere in the documentation. Several policies used
ambiguous language. For example, Merck Serono stated, as a
commitment: “All Merck Serono clinical trials in patients will
be considered [our emphasis] for publication in the scientific
literature, regardless of outcome.” Similarly, several policies
included poorly defined caveats about which trials were covered
by the commitments. For example, Purdue “has committed to
publish in a publicly available database the results of many of
its clinical trials”; and Sanofi commits to post results for “phase
I to IV clinical trials conducted in patients, and for some [our
emphasis] vaccines trials conducted in healthy subjects.” Some
companies made commitments so broad that they were either
improbable or contradicted by other parts of the policy. For
example, Lundbeck lists a series of exclusions to its transparency
policy, setting out those trials of which they will not report
results, but also said it adheres to the Declaration of Helsinki,
which requires all results to be made publicly available. Further
anomalies were identified. Some companies committed to share
results on platforms that do not appear to exist. Several
companies’ policies contained clauses implying concern that
sharing summary results within a 12 month timeline required
by various regulations would compromise academic journal
publication.
We did, however, also find examples of good policies and
exemplary clear language. For example,Merck explicitly states
that it applies “the same ethical standards to clinical trials in all
countries including the developing world”; whereas
Bristol-Myers Squibbmakes an uncommon explicit commitment
to submitting all phase IV trials for journal publication (“We
commit to submitting all phase III and IV clinical trials
regardless of outcome to peer reviewed journals for
publication”). Conversely, Novartis explicitly excludes phase
IV trials from CSR and IPD sharing: although less than ideal,
the policy is clear and unambiguous on this issue.
Coding challenges
We encountered various coding challenges. Some companies
had different policies for trials in different territories. Because
clinical trials research is a mobile global enterprise we coded
according to the elements of the policy that applied globally.
Some companies committed to adhere to the law on sharing
summary results (eg, Pfizer: “after the completion of those
studies, we provide results on clinicaltrials.gov and other
registries, in accordance with local regulations and guidelines”).
However, these statements are difficult to interpret, since the
regulations and guidelines themselves are often poorly specified
and implemented: for example, the rules implementing the FDA
Amendment Act 2007 were still not published when this audit
was completed, and they do not apply to all trials. We therefore
scored companies for a commitment only if it was explicitly
stated what they would share, rather than alluding to compliance
with regulations. Some companies stated they shared information
on trials for treatments that were either approved or where the
research programme was terminated. We coded these as not
committing to share results of trials on unapproved medicines
(or off-label uses of approved medicines) because the process
of termination is discretionary and may not happen within a
consistent timeframe. Related to this, many companies stated
they will submit results of previous trials to clinicaltrials.gov
but gave no timeline: again, this meant results might never
appear and yet not formally breach the company’s policy
commitments. Undated documents often made it impossible to
assess how far back policies go; for these companies we could
not give a policy start date. Where policy start dates were given,
it was challenging to make dates comparable between
companies, as some stated “trials started after” a given date,
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some “trials completed after” a given date, some “drugs
approved after” a given date, and some simply gave a date
without further specification. We normalised dates using the
method described in web appendix 1.
Company feedback
When sent details of our extracted summary of their
commitments, 23/42 companies (55%) replied. These replies
were highly variable in length (mean 12 pages, range 1-39) and
content. Two companies (Pfizer andGlaxoSmithKline) provided
publicly accessible documents we had not found by searching
companies’ websites. Neither document was easily discoverable
by anyone seeking a company’s public policy: both had been
prepared by communications departments (a press release and
a policy PDF), both were housed in the media section of the
website, neither were linked from other parts of their site, and
both had onlyminimal links from the wider internet (on a refined
Google search for “pages linking to” the web addresses for these
documents). We accepted both, however, as the companies
provided evidence that they were publicly accessible at April
2016. Combining the two additional policy documents, and 217
pages of company responses in total, raising over 300 points of
contention, we identified seven elements in our database that
we changed in the light of critical feedback of our assessments
from companies: this was 0.4% (7/1806) of all coded policy
elements. The full raw text of all responses is shared as
underlying raw data alongside our own data sheets for each
company.40
Several companies acknowledged that their policy was
ambiguous, or indicated that their policy did not reflect their
actions. Specifically: 11 stated that their actions exceeded their
public policy commitments, four stated that they will change
their public policy in response to our contact, three stated that
they planned to change their policy, without being explicit that
this was in response to our contact, and four stated that they had
already made a change to their public policies on the issues we
raised, without being clear whether this was in response to our
contact. Some responses about policy changes were problematic.
In challenging our coding, some company responses were
constructive, making reference to specific phrases in their
policies the reading of which they wished to contest. However,
most were lengthy, used vague language, and failed to address
the specific questions raised. There were recurring themes in
responses. Four companies argued that our coding of their public
policy was wrong, but the evidence they gave for this assertion
was a private document not available in the public domain, such
as an internal standard operating procedure. Five companies
stated that our coding of their public policy was wrong, but gave
no evidence as to why, and their response was not consistent
with their public policy. Three companies argued that it was
unfair to describe the limitations on their IPD or CSR sharing
commitments because they also considered applications for data
and documents that fall outside these commitments (this
commitment was coded separately in our audit). Notably, Novo
Nordisk stated in its response to our coding: “Just for reference,
we do not say it anywhere, because we do not want to encourage
submission of research proposals that go beyond the stated
scope, but we do actually consider all received proposals.”
Discrepancies between industry commitments
and individual companies’ commitments
We examined whether all members of the industry bodies made
commitments that match the minimum collective commitments
made in the “Joint Position” commitments (which cover only
trial registration and results sharing) from pharmaceutical
industry bodies. Twenty two companies were members of
Pharmaceutical Research and Manufacturers of America
(PhRMA). Of these, two companies’ policies did not reflect the
commitment on registration in the European Federation of
Pharmaceutical Industries and Associations (EFPIA)/PhRMA/
International Federation of Pharmaceutical Manufacturers and
Associations (IFPMA)/Japan Pharmaceutical Manufacturers
Association (JPMA) “Joint Principles” 2005 (and the updated
version of 2009); and three did not reflect the same documents’
commitments to share summary results. We asked EFPIA and
PhRMA whether the joint position commitments are to be read
as binding on all members. They replied: “Although, the
Principles are voluntary, the PhRMA and EFPIA Boards
encourage member companies to adhere to the principles and
confirm the implementation of data sharing procedures through
publicly available letters of certification.”
During coding we also found that in addition to membership
five companies explicitly stated that they commit to the industry
bodies’ “Joint Position” documents (either 2009, 2005, or
without specifying which). We therefore additionally tested for
discrepancies between these companies’ own explicit
commitments and the industry body commitments, to examine
whether our coding should be changed or upgraded in light of
their stated adherence to an external policy. No changes were
warranted. The “Principles on Data Sharing 2013” document
from EFPIA and PhRMA commits a company to having an
application process for sharing CSRs and IPD, both from 2014
onwards. Again, during coding we found companies who stated
that they implemented these principles; we therefore tested to
check whether our coding of their policy matched the minimum
standard of that external document. Two (Orion and Abbott)
were coded as “no” for sharing CSRs on request, based on their
own policy documents; arguably these companies could inherit
a “yes” for this policy issue, from endorsing the wider industry
body document.
Discussion
Company policies and actions on transparency vary widely
across all domains. With one exception (journal submission for
all trials within 12 months) all aspects of the reference standard
were met by at least one company, showing that these
commitments are realistic targets, judged as reasonable by at
least one company. Company policies commonly used unclear
language and exhibited internal contradictions.Many companies
lacked commitments on basic issues such as trial registration
and the sharing of summary results. Transparency commitments
generally did not include trials for off-label uses, even though
these are common in clinical practice; and commonly failed to
include phase IV trials. Twenty three companies replied when
given our appraisal of their policy. Feedback was lengthy, but
often ambiguous, and only had a minor impact on our coding:
0.4% of score elements were changed. However, 10 of the
companies who responded informed us they were changing their
public policies, and four explicitly stated that this was as a result
of feedback from our research.
Strengths and limitations of this study
This is the first audit of company policies on trials transparency,
an important public health issue. It focused on one
methodological and policy issue, measuring clear objective
outcomes. All extracted data are shared openly so that others
can critically review all coding. Some companies declined to
reply when contacted about our assessment of their
commitments: however, since this was an audit of public
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commitments, and company replies identified almost no required
changes, we do not believe this substantially affected the
accuracy of extracted data. All raw data and source documents
are shared in full to allow others to validate or critically review
data extraction. As with all projects of this kind, alternative data
frames could have been constructed. Ideally, data on various
additional features would have been extracted, including: a
measure for the time burden on applicants for access to clinical
study reports (CSRs) (as some companies share proactively or
on simple request, whereas some require full protocol from the
applicant, and a curriculum vitae for team members); separate
ascertainment of different transparency commitments for trials
conducted in different territories, or other classes of trial (eg,
investigator initiated trials funded by the company), and more
detailed differentiation of limitations on access to CSRs and
individual patient data (IPD). However, since it was established
during coding that policies were often unclear on basic issues,
such additional efforts may prove challenging until companies
can move towards less ambiguous policies.
The last limitations relate to scope. Our audit was focused on
companies: policies from non-industry sponsors will be
addressed in a separate study. In addition, our audit intentionally
assessed companies’ commitments, not their performance:
delivering the latter would require ongoing public audit of all
trials conducted by all companies to establish what proportion
had their methods, results, CSRs, and IPD made available.
Although desirable,8 such an audit across all aspects of sharing
across all trials would require extensive resources. Previous
attempts to compare companies’ performance have therefore
only focused on registration and the availability of results;
additionally they have used either small samples of trials13 or
automated approaches processing metadata on larger samples,41
resulting in pragmatic compromises between coverage, accuracy,
and precision.
Context of other research
To our knowledge this is the first structured audit and
benchmarking project to examine the transparency policies of
pharmaceutical companies. The Access to Medicines Index is
similar in its intent to grade performance of companies on a
complex public health policy issue and has been successful at
drawing greater attention to access to medicines and guiding
policy discussions on how to facilitate change. Additionally, a
2014 editorial summarises 12 companies’ IPD sharing policies
in free text,42 and one team in 200843 reviewed research policies
from selected charities, government bodies, and research
councils, but not from pharmaceutical companies: it found that
26% mentioned trial registration explicitly, 40% mentioned
registration implicitly through reference to other guidelines,
and 67% mentioned trial publication explicitly. These figures
are consistent with our findings.
Interpretation and policy implications
We found extensive heterogeneity in policies, and several
concerning omissions. While larger companies had more
complete policies, only 71% of all companies had a commitment
to register all trials, the most basic level of transparency; and
only 71%had a commitment to share summary results. Company
transparency policies overwhelmingly failed to include trials
on unlicensed uses of currently marketed products, even though
such use is common in clinical practice, and widely promoted
outside the law by companies as shown by extensive recent
court cases and fines.44 45 46 47Only 52% included phase IV trials
under their transparency policies. Median start dates for
transparency commitments were so recent as to exclude the
majority of trials on currently used treatments, not just for CSR
and IPD sharing (2012) but also for registration and summary
results (2005).
We also identified several recurring shortcomings in policies
that have not been previously systematically identified. For
example, several companies made access to CSRs contingent
on approval of a medicine in both the EU and the USA: this
means that CSRs would be inaccessible for any indication or
medicine approved only in the EU or USA, such as testosterone
injections for female sexual dysfunction, or the antidepressant
reboxetine; or for treatments marketed in Africa but unapproved
in the EU and USA. This is particularly problematic, since
treatments rejected by some regulators are likely to be those
where the risks and benefits are more closely balanced, and
therefore where access to the methods and results of studies
underlying regulatory decisions is more important.
The ambiguity in company policies made interpretation and
data extraction difficult. Policies were often long, spread over
multiple documents or web pages, internally contradictory, and
used vague language. This is surprising, given that companies
have access to extensive legal and regulatory expertise. The
feedback from companies suggests that their own policies often
do not reflect their internal practices. This makes appraising
their compliance with their own policies extremely challenging
both for external actors and, presumably, for themselves. We
suggest that company policies should be simple, easily
interpretable, and, ideally, standardised. We propose a simple
boilerplate transparency policy in box 2.
We intend that the benchmarking exercise reported here can be
used by companies to review their own practice, and identify
where their policies can be improved: this is supported by the
number of companies that responded positively when presented
with a structured interpretation of their public policies. We also
intend that our findings can be used by regulators, patient
groups, professional bodies, ethical investors, and healthcare
workers to advocate for improvement at companies with less
stringent transparency policies, or to guide procurement
decisions.
All results will be presented on a standalone website,40 with
accompanying contextual information and links, to increase
accessibility for the data and augment impact on practice. We
also anticipate that this resource may assist those seeking access
to individual trial results, by widening easier access to a
summary of the specific commitments made by each individual
company. We are already aware of individual cases where
company spokespeople have refused access to trial results, and
mischaracterised their own company’s policy, in correspondence
with systematic reviewers seeking access to information on a
specific trial. This may reflect the lack of clarity in some
companies’ policies, leading to misunderstandings for staff; or
a broader lack of informed public discourse around companies’
commitments. Our publication of company policy commitments
in an accessible format may lead to further examples of
companies apparently breaching the commitments summarised
here; this will provide important information on how companies’
policy commitments are applied in practice.
Future research
Following best practice in assessing impact from audit and
feedback we intend to repeat this audit. We welcome
methodological criticisms and suggestions to improve the data
schema. In addition we are developing a new benchmarking
framework to grade actions and policies on transparency by
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Box 2: Model pharmaceutical company clinical trial transparency policy
RegistrationWe commit to register all clinical trials conducted in all territories, before trial commencement. For clarity this policy includes:
phase I/II/III/IV trials; trials in the following territories (specify). This policy has been in place since [date].
Summary methods and results We commit to make the methods and summary results of all clinical trials publicly available within XX
months of completion. These will be posted on clinicaltrials.gov/our own website. These will be posted as free text/CSR synopses/structured
summary data, with accompanying protocols/statistical analysis plans [delete as applicable]. For clarity, this policy includes [delete as
applicable] trials on unapproved treatments, trials on unapproved uses of approved treatments, phase I/II/III/IV trials, all trials in all
territories/all trials in the following countries (specify). This policy applies retrospectively and covers trials that: started after [date]/completed
after [date]/treatments approved after [date]. In addition, all/some (specify which) trials will be submitted to an academic journal within
XX months of completion.
Clinical study reports (CSRs) We commit to share full CSRs, for all clinical trials with an associated CSR, within XX months of trial
completion. These will be posted on: our own website/EU clinical trials registry (but note this only covers EU trials)/clinical study data
request site/an independent repository (specify which)]. For clarity, this policy includes [delete as applicable]: trials on unapproved
treatments; trials on unapproved uses of approved treatments; phase I/II/III/IV trials; all trials in all territories / all trials in the following
countries (specify). This policy applies retrospectively and covers trials that started after [date]/completed after [date]/treatments approved
after [date]. Our redactions policy for full CSRs can be read in one document, here [link]. We make CSRs available by posting proactively
on a public website [link to website]/a “light touch” requests process open to all, where applicants only specify the document they are
requesting [link to requests portal]/a review process where applicants submit CVs and describe why they want access to a CSR [link to
request portal and guidance on access control].
Individual patient data (IPD)We commit to share IPD on request, for all clinical trials, within XX months of trial completion. Our IPD can
be accessed through: our own website/EU clinical trials registry (but note this only covers EU trials)/clinical study data request site/an
independent repository [specify which]. For clarity, this policy includes [delete as applicable]: trials on unapproved treatments, trials on
unapproved uses of approved treatments, phase I/II/III/IV trials, all trials in all territories/all trials in the following countries (specify). This
policy applies retrospectively and covers trials that: started after [date]/completed after [date]/treatments approved after [date]. Our
applications process for IPD can be read in one document, here [link].
academic journals, academic institutions, and non-commercial
trial sponsors.
Conclusion
Public policies on transparency of trials are highly variable
between pharmaceutical companies, often ambiguous, and
inconsistent with the companies’ description of their own
commitments in correspondence. This makes appraising
companies’ compliance with their own policies extremely
challenging. Company transparency policies should be explicit,
with unambiguous statements describing how compliance is
monitored. Companies should also aspire to meet the standard
of all trials registered, with methods and results made available,
and with clear arrangements for sharing CSRs and IPD.
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Tables
Table 1| Proportion of companies meeting each transparency criteria
No (%) “yes”Question*
All companies (n=42)Top companies (n=23)
Registration
30 (71)21 (91)Do they have a policy to register all trials from now?†
2 (5)2 (9)Do they say they conduct any kind of audit of compliance with their registration policy?
29‡ (69)21‡ (91)Does the policy include phase IV trials?
21 (50)15 (65)Does their current policy describe the registration policy covering past trials?
Results
30 (71)22 (96)Do they have a policy to make all summary results available?†
13 (31)9 (39)
Do they commit to post summary results on prespecified primary and secondary outcomes
to clinicaltrials.gov within 12 months of completion?
7 (17)6 (26)
Do they commit to post summary results to their own website within 12 months of
completion?
0 (0)0 (0)
Do they commit to submit all trial results to an academic journal within 12 months of
completion?
8 (19)6 (26)Does this commitment to post summary results include unlicensed products?
8 (19)6 (26)Does this commitment to post summary results include off-label uses of licensed products?
22 (52)18 (78)Does this commitment to post summary results include phase IV trials?
22 (52)17 (74)
Does their current policy cover results of past trials, committing to make all results
available?†
Clinical study reports (CSRs)
28 (67)22 (96)Do they have a policy on sharing CSRs at all?
27 (64)21 (91)Do they commit to share CSRs?
22 (52)17 (74)Is access to CSRs on request only, rather than prospectively posting CSRs online?
2 (5)2 (9)Does this commitment to sharing CSRs include trials on unlicensed products?
2 (5)2 (9)Does this commitment to sharing CSRs include off-label uses of licensed products?
3 (7)2 (9)Does the policy commit to sharing synopses only?
27 (64)21 (91)Does their current policy cover CSRs of past trials?
Individual patient data (IPD)
30 (71)22 (96)Do they have a policy to make IPD from clinical trials available on request?
1 (2)1 (4)Does this commitment to sharing IPD include trials on unlicensed products?
1 (2)1 (4)Does this commitment to sharing IPD include off-label uses of licensed products?
17 (40)14 (61)Does the policy include phase IV trials?
16 (38)12 (52)
Do they say they consider requests for IPD on additional trials not explicitly covered by
their policy?
*Further details in web appendix 1.
†Excepting specific exclusions discussed.
‡This number excludes Roche, as they have an unclear policy on registering all trials, while the phase IV element of their policy is less ambiguous.
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Research and Manufacturers of America.
*See web appendix 1 for normalisation.
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Table 3| Summary of start dates for policy commitment in each of the four policy domains
All companiesTop companies
Policy domain Latest dateEarliest date
Median of all companies giving a
dateLatest dateEarliest date
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Table 4| Examples of shortcomings in pharmaceutical company transparency policies, arranged by theme
Examples*Themes and subthemes
Ambiguous, inconsistent, and contradictory language
Bristol-Myers Squibb states “We commit to submitting all phase III and IV clinical trials regardless of outcome to peer
reviewed journals for publication”; however, elsewhere they state that their other commitments for transparency (such
as synopses, or summary results on registers) are only for approved products and indications, and for trials completing
after 2008. It is highly likely that those caveats also apply to journal submission, but its written commitment is “all,” without
caveats
Problematic or contradictory use of the
term “all”
AbbVie states the company: “submits a manuscript, that at a minimum, reports the results of the primary endpoint, to a
peer-reviewed scientific/medical journal within 12 months, and no later than 18 months.” It is unclear whether this
commitment is to within 12 or 18 months
Ambiguous language
Merck Serono states: “All Merck Serono clinical trials in patients will be considered for publication in the scientific literature,
regardless of outcome” (our emphasis). This statement was described as a “commitment” in the document containing it
Purdue’s policy states: “In addition, Purdue has committed to publish in a publicly available database the results ofmany
of its clinical trials” (our emphasis)
Poorly defined caveats about trials
covered by the policy
Sanofi commits to post results for “phase I to IV clinical trials conducted in patients, and for some vaccines trials conducted
in healthy subjects” (our emphasis)
Pfizer’s policy about sharing clinical study reports (CSRs) is clear, but statements about its enactment are contradictory:
it initially said it posts synopses for all trials, then in the next sentence it said it had posted some. “Pfizer posts synopses
on our public website of Clinical Study Reports (documents prepared for regulators) for all trials registered on
clinicaltrials.gov. Many clinical study report synopses are now publicly posted, and additional clinical study report synopses
will be posted during 2014”
Inconsistency within document
Johnson and Johnson describes its individual patient data (IPD) sharing commitment in various places, but only one
mentions that it includes phase IV trials; the others, while being comprehensive on other issues, did not cover that important
inclusion
Inconsistency between documents
Limiting commitment to legal compliance
Pfizer commits to adhere to the law on sharing summary results: “After the completion of those studies, we provide results
on clinicaltrials.gov and other registries, in accordance with local regulations and guidelines”
-
Daiichi Sankyo’s entire transparency policy is: “Daiichi Sankyo registers and discloses clinical trial and result information
according to local regulations”
Commitments to share on platforms that do not exist, or contain only dead links
AstraZeneca’s current policy commits to posting information on an International Federation of Pharmaceutical Manufacturers
and Associations (IFPMA) portal that has not existed since 2011
-
AbbVie claimed that they had archived the contents of the now deleted IFPMA results portal onto a new site containing
all phase III and IV trial results since 2002. Although this initially appeared to be true, closer examination showed that it
was not. There is a list of trials maintained on AbbVie’s website. Clicking on “more” for any trial takes you to a page with
some brief further details on the existence of the trial. But the links for summary results on all trials clicked on went to a
dead “404 not found” page (https://youtu.be/S9mXeKbIrDU)
Issues arising from companies operating in multiple regions
Amgen has different policies for different territories: “In the United States: Amgen registers clinical trials and reports clinical
study results on www.clinicaltrials.gov for trials that were initiated after 27 September 2007 or ongoing as of 26 December
2007” and “In Europe: Amgen registers clinical trials and will post results on the EU Clinical Trial Register. Amgen
sponsored interventional clinical trials (phases I-IV) will be registered as follows: Where there is at least one participating
site within the European Union (EU), or the European Economic Area (EEA) which started after 1 May 2004”
Different policies for different regions
Lundbeck states it will share CSRs and IPD for “products approved in Europe and US after 1 January 2014” (our emphasis).
If this means a treatment must be approved in both of two continents to be shared, then information would be inaccessible
if the treatment was approved and being used in only one continent. Astellas imposes a similar limitation on CSR sharing
Requiring approval on two continents
before transparency
Other
Lundbeck lists a series of exclusions to its transparency policy, setting out the trials the results of which it will not report,
but also say they adhere to the Declaration of Helsinki, which requires all results to be made publicly available
Unrealistic and extreme transparency
commitments
Almirall states: “The results summary of the clinical trial . . . is published within a year . . . These schedules are subject
to adjustment . . . to avoid compromising publication in a peer-reviewedmedical journal.” This conflicts with the International
Committee of Medical Journal Editors statement that results sharing on a registry should not be regarded as previous
publication to prejudice journal acceptance
Concerns about transparency prejudicing
journal publication
AstraZeneca states: “When a medicine in development has been discontinued, results are published within one year of
the public announcement of the decision.” However, termination of a research programme is discretionary
Commitments on approved and
terminated treatments
*See web appendix 2 for further examples.
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